secwatch / observer
8-K filed June 3, 2026, 4:31 PM ET ticker AGL CIK 0001831097
other confidence high sentiment neutral materiality 0.10

agilon health annual meeting votes; all three proposals approved

agilon health, inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

agilon health, inc. shareholders approved Election of three Class II directors at the 2026-06-02 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-02
Exact text from the filing
The following three individuals were elected to the Company's Board of Directors to serve as Class II directors until the Company's 2029 annual meeting of stockholders and until their successors have been duly elected and qualified.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

agilon health, inc. shareholders approved Non-binding vote on executive compensation at the 2026-06-02 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-02
Exact text from the filing
The stockholders approved, on an advisory, non-binding basis, the compensation paid to the Company’s named executive officers.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

agilon health, inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-02 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-02
Exact text from the filing
The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
View on SEC.gov

404 shareholder votes filed in the last 30 days. Browse all shareholder votes →

agilon health, inc. filing history →

Source: SEC EDGAR
accession 0001628280-26-040370
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.